COMMUNIQUÉS West-GlobeNewswire

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
25/01/2024
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The [...]
Cronos’ Spinach® Brand Ends 2023 as the Number One Flower Brand in Canada1
25/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that its brand, Spinach ® , closed 2023 as [...]
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
25/01/2024
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024 Pamrevlumab is the first experimental arm to meet its [...]
Embrace the Taste of Paradise with Breckenridge Brewery’s Refreshing New ‘Juicy Oasis Fruited Hazy IPA’
25/01/2024
LITTLETON, Colo., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brewery” or “Breck Brew”) a subsidiary of Tilray Brands, Inc . (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), is thrilled to [...]
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
25/01/2024
Interim Data Analysis Anticipated in Mid-2024 Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive [...]
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25/01/2024
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business Officer NEW YORK and [...]
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25/01/2024
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the [...]
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25/01/2024
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort participants who crossed [...]
Le KFSH&RC honore 25 scientifiques nommés dans le classement de Stanford parmi les 2 % des chercheurs les plus cités au monde
25/01/2024
RIYAD, Arabie Saoudite, 25 janv. 2024 (GLOBE NEWSWIRE) -- L’hôpital spécialisé et centre de recherche King Faisal (KFSH&RC) a honoré les 25 scientifiques ayant rejoint le prestigieux classement de l’Université de [...]
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25/01/2024
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid [...]
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
25/01/2024
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomized Net revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year [...]
Nicox : Résumé financier et point d’activité du quatrième trimestre 2023
25/01/2024
Communiqué de presse Nicox : Résumé financier et point d’activité du quatrième trimestre 2023 Randomisation de 75% des patients de l'étude clinique de phase 3 Denali sur le NCX 470 Chiffre d’affaires net de €1,3 million [...]
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
25/01/2024
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee osteoarthritis, an [...]
BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
25/01/2024
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une approche récemment publiée [...]
AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device
25/01/2024
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device [...]
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
24/01/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation [...]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
24/01/2024
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]

Pages